At least we know all the parameters, and that the ASX is watching.
I am heartened by what seems to be a probability there will be no CR, due to sale of the infusion business.
Adapt sales also seem likely to increase as the new products gain traction, particularly with imminent regulatory approvals.
If there is a partnership, then that changes everything. The interim results published yesterday seem to make that more likely.
It seems to me there are plenty of pieces still on the board.
Ann: Response to ASX Appendix 4C Query, page-8
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.00 |
Change
0.000(0.00%) |
Mkt cap ! $253.6M | |||
| Open | High | Low | Value | Volume |
| $11.88 | $12.00 | $11.50 | $261.8K | 22.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 156 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.00 | 6045 | 3 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |